Partnership expands to create mRNA vaccines

Partnership expands to create mRNA vaccines
Partnership expands to create mRNA vaccines | Courtesy of biology.usf.edu
CureVac, a clinical-stage biopharmaceutical company that is a pioneer in the field of mRNA-based technology, said Tuesday it has launched its third target product development program in collaboration with the Bill & Melinda Gates Foundation.

The program will utilize CureVac's RNActive technology platform to create a prophylactic vaccine designed to protect people from contract respiratory syncytial virus (RSV).

There are two other development programs involving the Gates Foundation and CureVac. These were dedicated to targeting mRNA vaccines for rotavirus and HIV. 

The Centers for Disease Control and Prevention (CDC) confirmed that RSV is considered a common virus during the winter, fall and spring seasons. It is transmitted from person to person by sneezing and coughing. Elderly adults and infants are especially susceptible to the virus. As of today, there is no vaccine that protects people from RSV infections.

"We're pleased to intensify our collaboration with the Bill & Melinda Gates Foundation with this RSV vaccine development-program," CureVac CEO Ingmar Hoer said. "This project is our third infectious disease program to be developed in collaboration with the foundation, and we are honored to have the opportunity to utilize our mRNA technology to fight a host of diseases that have a disproportionate impact on the world's poorest countries."

Organizations in this Story


Want to get notified whenever we write about CureVac ?
Next time we write about CureVac, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.